NCT03657576View on ClinicalTrials.gov

Trial of C134 in Patients With Recurrent GBM

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

October 25, 2024

Study Completion Date

September 30, 2026

Conditions
Glioblastoma Multiforme of BrainAnaplastic Astrocytoma of BrainGliosarcoma of Brain
Interventions
BIOLOGICAL

C134

C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER